Jiang Qianqian, Tong Fei, Xu Yun, Liu Cheng, Xu Qiaoping
Department of Pharmacy, Traditional Chinese Medicine Hospital of Changshan, Quzhou, 324200, P.R. China.
Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510280, P.R. China.
Cancer Cell Int. 2024 Dec 19;24(1):414. doi: 10.1186/s12935-024-03572-2.
Breast cancer (BC) is the leading cause of cancer-related mortality among women globally, affecting approximately one-quarter of all female cancer patients and accounting for one-sixth of cancer-related deaths in women. Despite significant advancements in diagnostic and therapeutic approaches, breast cancer treatment remains challenging due to issues such as recurrence and metastasis. Recently, a novel form of regulated cell death, termed cuproptosis, has been identified. This process disrupts mitochondrial respiration by targeting the copper-dependent cellular pathways. The role of cuproptosis has been extensively investigated in various therapeutic contexts, including chemotherapy, immunotherapy, radiotherapy, and nanotherapy, with the development of novel drugs significantly improving clinical outcomes. This article aims to further elucidate the connection between cuproptosis and breast cancer, focusing on its therapeutic targets, signaling pathways, and potential biomarkers that could enhance treatment strategies. These insights may offer new opportunities for improved patient care and outcomes in breast cancer therapy.
乳腺癌（BC）是全球女性癌症相关死亡的主要原因，约占所有女性癌症患者的四分之一，占女性癌症相关死亡的六分之一。尽管在诊断和治疗方法上取得了重大进展，但由于复发和转移等问题，乳腺癌治疗仍然具有挑战性。最近，一种新型的程序性细胞死亡形式，称为铜死亡，已被确定。这个过程通过靶向铜依赖性细胞途径破坏线粒体呼吸。铜死亡的作用已在各种治疗背景下进行了广泛研究，包括化疗、免疫疗法、放射疗法和纳米疗法，新型药物的开发显著改善了临床结果。本文旨在进一步阐明铜死亡与乳腺癌之间的联系，重点关注其治疗靶点、信号通路以及可能增强治疗策略的潜在生物标志物。这些见解可能为改善乳腺癌治疗中的患者护理和治疗结果提供新的机会。
